Abstract
Doxorubicin in a dose of 60 mg/m2 has been used in the treatment of 23 patients with advanced malignant disease, 18 of whom had carcinoma of the breast. The drug has significant clinical activity on its own, prolonged dosage may be required to obtain a response, and there is a risk of cerebral metastases becoming manifest during treatment which is otherwise successful. Cardiac toxicity appears to be acceptably low with this dose regimen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Cole, M., Todd, I. & Wilkinson, P. A Preliminary Trial of Doxorubicin in Advanced Breast Cancer and Other Malignant Disease. Br J Cancer 29, 114–116 (1974). https://doi.org/10.1038/bjc.1974.47
Issue Date:
DOI: https://doi.org/10.1038/bjc.1974.47
This article is cited by
-
Chemotherapy of thyroid carcinoma
Journal of Endocrinological Investigation (1987)